Gadospin f-enhanced magnetic resonance imaging for diagnosis and monitoring of atherosclerosis: validation with transmission electron microscopy and x-ray fluorescence imaging in the apolipoprotein e-deficient mouse

Standard

Gadospin f-enhanced magnetic resonance imaging for diagnosis and monitoring of atherosclerosis: validation with transmission electron microscopy and x-ray fluorescence imaging in the apolipoprotein e-deficient mouse. / Jung, Caroline; Dučić, Tanja; Reimer, Rudolph; Koziolek, Eva; Kording, Fabian; Heine, Markus; Adam, Gerhard; Ittrich, Harald; Kaul, Michael G.

in: MOL IMAGING, Jahrgang 13, 2014, S. 1-10.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{df1804f9979145c481ae59b4d8aa2d22,
title = "Gadospin f-enhanced magnetic resonance imaging for diagnosis and monitoring of atherosclerosis: validation with transmission electron microscopy and x-ray fluorescence imaging in the apolipoprotein e-deficient mouse",
abstract = "AbstractThe aim of this study was to investigate the feasibility of noninvasive monitoring of plaque burden in apolipoprotein E-deficient (ApoE-/-) mice by Gadospin F (GDF)-enhanced magnetic resonance imaging (MRI). Gadolinium uptake in plaques was controlled using transmission electron microscopy (TEM) and x-ray fluorescence (XRF) microscopy. To monitor the progression of atherosclerosis, ApoE-/- (n  =  5) and wild-type (n  =  2) mice were fed a Western diet and imaged at 5, 10, 15, and 20 weeks. Contrast-enhanced MRI was performed at 7 T Clinscan (Bruker, Ettlingen, Germany) before and 2 hours after intravenous injection of GDF (100 μmol/kg) to determine the blood clearance. Plaque size and contrast to noise ratio (CNR) were calculated for each time point using region of interest measurements to evaluate plaque progression. Following MRI, aortas were excised and GDF uptake was cross-validated by TEM and XRF microscopy. The best signal enhancement in aortic plaque was achieved 2 hours after application of GDF. No signal differences between pre- and postcontrast MRI were detectable in wild-type mice. We observed a gradual and considerable increase in plaque CNR and size for the different disease stages. TEM and XRF microscopy confirmed the localization of GDF within the plaque. GDF-enhanced MRI allows noninvasive and reliable estimation of plaque burden and monitoring of atherosclerotic progression in vivo.",
author = "Caroline Jung and Tanja Du{\v c}i{\'c} and Rudolph Reimer and Eva Koziolek and Fabian Kording and Markus Heine and Gerhard Adam and Harald Ittrich and Kaul, {Michael G}",
year = "2014",
doi = "10.2310/7290.2014.00039",
language = "English",
volume = "13",
pages = "1--10",
journal = "MOL IMAGING",
issn = "1535-3508",
publisher = "Decker Publishing",

}

RIS

TY - JOUR

T1 - Gadospin f-enhanced magnetic resonance imaging for diagnosis and monitoring of atherosclerosis: validation with transmission electron microscopy and x-ray fluorescence imaging in the apolipoprotein e-deficient mouse

AU - Jung, Caroline

AU - Dučić, Tanja

AU - Reimer, Rudolph

AU - Koziolek, Eva

AU - Kording, Fabian

AU - Heine, Markus

AU - Adam, Gerhard

AU - Ittrich, Harald

AU - Kaul, Michael G

PY - 2014

Y1 - 2014

N2 - AbstractThe aim of this study was to investigate the feasibility of noninvasive monitoring of plaque burden in apolipoprotein E-deficient (ApoE-/-) mice by Gadospin F (GDF)-enhanced magnetic resonance imaging (MRI). Gadolinium uptake in plaques was controlled using transmission electron microscopy (TEM) and x-ray fluorescence (XRF) microscopy. To monitor the progression of atherosclerosis, ApoE-/- (n  =  5) and wild-type (n  =  2) mice were fed a Western diet and imaged at 5, 10, 15, and 20 weeks. Contrast-enhanced MRI was performed at 7 T Clinscan (Bruker, Ettlingen, Germany) before and 2 hours after intravenous injection of GDF (100 μmol/kg) to determine the blood clearance. Plaque size and contrast to noise ratio (CNR) were calculated for each time point using region of interest measurements to evaluate plaque progression. Following MRI, aortas were excised and GDF uptake was cross-validated by TEM and XRF microscopy. The best signal enhancement in aortic plaque was achieved 2 hours after application of GDF. No signal differences between pre- and postcontrast MRI were detectable in wild-type mice. We observed a gradual and considerable increase in plaque CNR and size for the different disease stages. TEM and XRF microscopy confirmed the localization of GDF within the plaque. GDF-enhanced MRI allows noninvasive and reliable estimation of plaque burden and monitoring of atherosclerotic progression in vivo.

AB - AbstractThe aim of this study was to investigate the feasibility of noninvasive monitoring of plaque burden in apolipoprotein E-deficient (ApoE-/-) mice by Gadospin F (GDF)-enhanced magnetic resonance imaging (MRI). Gadolinium uptake in plaques was controlled using transmission electron microscopy (TEM) and x-ray fluorescence (XRF) microscopy. To monitor the progression of atherosclerosis, ApoE-/- (n  =  5) and wild-type (n  =  2) mice were fed a Western diet and imaged at 5, 10, 15, and 20 weeks. Contrast-enhanced MRI was performed at 7 T Clinscan (Bruker, Ettlingen, Germany) before and 2 hours after intravenous injection of GDF (100 μmol/kg) to determine the blood clearance. Plaque size and contrast to noise ratio (CNR) were calculated for each time point using region of interest measurements to evaluate plaque progression. Following MRI, aortas were excised and GDF uptake was cross-validated by TEM and XRF microscopy. The best signal enhancement in aortic plaque was achieved 2 hours after application of GDF. No signal differences between pre- and postcontrast MRI were detectable in wild-type mice. We observed a gradual and considerable increase in plaque CNR and size for the different disease stages. TEM and XRF microscopy confirmed the localization of GDF within the plaque. GDF-enhanced MRI allows noninvasive and reliable estimation of plaque burden and monitoring of atherosclerotic progression in vivo.

U2 - 10.2310/7290.2014.00039

DO - 10.2310/7290.2014.00039

M3 - SCORING: Journal article

C2 - 25342533

VL - 13

SP - 1

EP - 10

JO - MOL IMAGING

JF - MOL IMAGING

SN - 1535-3508

ER -